This R&D Briefing presents data from HTADock, an ongoing metrics study that collects publicly available data on new active substances (NASs) appraised by key international HTA agencies, each with unique perspectives and methodologies:
- Australian Pharmaceutical Benefits Advisory Committee (PBAC)
- Canadian Agency for Drugs and Technologies in Health (CADTH)
- English National Institute for Health and Care Excellence (NICE)
- French Haute Autorité de Santé (HAS)
- German Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
- Polish Agencja Oceny Technologii Medycznych i Taryfikacji (AOTMiT)
- National Health Care Institute in Netherlands (ZIN)
- Scottish Medicines Consortium (SMC)
- Swedish Tandvårds & läkemedelsförmånsverket (TLV).
The project explores the synchronisation between the regulatory and HTA landscapes, aiming to increase the transparency of the outcomes and timelines of HTA assessments. It also seeks to facilitate the enhancement of performance within HTA agencies.
The HTADock study will release three briefings in 2024, with this document being the first in the series. The subsequent sections of this briefing provide a thorough examination of the current HTA landscape in Australia, Canada, Europe, and the UK. The second briefing will focus regionally on Australia-Canada-UK, including analyses on Access work sharing and Project Orbis, while the third and final briefing will focus on EU jurisdictions.
If you have any questions or comments on this Briefing, please don’t hesitate to get in touch with Dr Tina Wang: twang@cirsci.org
